Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations

被引:56
|
作者
da Costa, Roner F. [2 ]
Freire, Valder N. [2 ]
Bezerra, Eveline M. [3 ]
Cavada, Benildo S. [4 ]
Caetano, Ewerton W. S. [1 ]
de Lima Filho, Jose L. [5 ]
Albuquerque, Eudenilson L. [6 ]
机构
[1] Inst Fed Educ Ciencia & Tecnol Ceara, BR-60040531 Fortaleza, Ceara, Brazil
[2] Univ Fed Ceara, Dept Fis, BR-60455760 Fortaleza, Ceara, Brazil
[3] Univ Fed Ceara, Fac Med, BR-62042280 Sobral, Brazil
[4] Univ Fed Ceara, Dept Bioquim, BR-60455760 Fortaleza, Ceara, Brazil
[5] Univ Fed Pernambuco, Lab Imunopatol Keizo Azami, BR-50670901 Recife, PE, Brazil
[6] Univ Fed Rio Grande do Norte, Dept Biofis & Farmacol, BR-59072970 Natal, RN, Brazil
关键词
D O I
10.1039/c1cp22824b
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
By taking advantage of the crystallographic data of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) complexed with statins, a quantum biochemistry study based on the density functional theory is performed to estimate the interaction energy for each statin when one considers binding pockets of different sizes. Assuming a correlation between statin potency and the strength of the total HMGR-statin binding energy, clinical data as well as IC50 values of these cholesterol-lowering drugs are successfully explained only after stabilization of the calculated total binding energy for a larger size of the ligand-interacting HGMR region, one with a radius of at least 12.0 angstrom. Actually, the binding pocket radius suggested by classic works, which was based solely on the interpretation of crystallographic data of the HMGR-statin complex, is smaller than that necessary to achieve total binding energy convergence in our simulations. Atorvastatin and rosuvastatin are shown to be the most strongly bound HMGR inhibitors, while simvastatin and fluvastatin are the weakest ones. A binding site, interaction energy between residues and statin atoms, and residues domain (BIRD) panel is constructed, indicating clear quantum biochemistry-based routes for the development of new statin derivatives.
引用
收藏
页码:1389 / 1398
页数:10
相关论文
共 50 条
  • [31] Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor
    Bose, Sucharita
    Steussy, C. Nicklaus
    Lopez-Perez, Daneli
    Schmidt, Tim
    Kulathunga, Samadhi C.
    Seleem, Mohamed N.
    Lipton, Mark
    Mesecar, Andrew D.
    Rodwell, Victor W.
    Stauffacher, Cynthia V.
    COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [32] Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake
    Vasconcelos, OM
    Campbell, WW
    MUSCLE & NERVE, 2004, 30 (06) : 803 - 807
  • [33] Various HMG-CoA reductase inhibitors
    Thiery, J
    Seidel, D
    INTERNIST, 1999, 40 (01): : 113 - 114
  • [34] DRUGS INHIBITING HMG-COA REDUCTASE
    ENDO, A
    PHARMACOLOGY & THERAPEUTICS, 1985, 31 (03) : 257 - 267
  • [35] HMG-CoA reductase inhibitors and the kidney
    Vito M. Campese
    Bassel Hadaya
    Josephine Chiu
    Current Hypertension Reports, 2005, 7 : 337 - 342
  • [36] HMG-CoA reductase inhibitors and apoptosis
    Senatore, M
    Buemi, M
    NEPHRON, 1999, 81 (04): : 439 - 440
  • [37] POSTTRANSCRIPTIONAL REGULATION OF HMG-COA REDUCTASE
    STRAKA, M
    DOGGETT, JK
    PANINI, SR
    FASEB JOURNAL, 1993, 7 (07): : A1232 - A1232
  • [38] Comparing HMG-CoA reductase inhibitors
    Jones, PH
    CLINICAL CARDIOLOGY, 2003, 26 (01) : I15 - I20
  • [39] Diplopia and HMG-CoA reductase inhibitors
    Fraunfelder, FW
    Fraunfelder, FT
    Edwards, R
    JOURNAL OF TOXICOLOGY-CUTANEOUS AND OCULAR TOXICOLOGY, 1999, 18 (04): : 287 - 289
  • [40] HMG-COA REDUCTASE INHIBITORS AND SLEEP
    SPIELBERG, SP
    TOBERT, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) : 109 - 110